trending Market Intelligence /marketintelligence/en/news-insights/trending/CGGQ0Ymytzl6X1usc5WV_Q2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Celyad to pay $25M in cash, shares for greater share in oncology assets

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Celyad to pay $25M in cash, shares for greater share in oncology assets

Celyad SA said it will pay $12.5 million in cash and issue $12.5 million worth of its shares for a greater share of the future revenues generated by certain CAR-T cell therapies for the treatment of cancer.

Celyad had obtained access to the assets after the acquisition of OnCyte LLC from privately held Celdara Medical LLC in 2015. The assets were developed using technology licensed from the Dartmouth College.

Celyad will make the payment to Celdara Medical LLC and Dartmouth College. The development reflects increased confidence in the future potential of the assets, including CYAD-01.

Celyad said it will use the money received from Novartis AG to partially cover the cash portion of the agreement.